Foghorn Therapeutics (FHTX) Stock Rating Cut by Wedbush

Wedbush downgraded Foghorn Therapeutics (FHTX) following a setback related to its drug development. The specific reasons for the downgrade were not disclosed in the article. This change in rating could signify potential challenges for the company in meeting market expectations and raise concerns among investors. The announcement highlights the need for investors to stay informed about developments that may affect Foghorn's performance in the market.